Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The price of Processa Pharmaceuticals Inc (NASDAQ: PCSA) closed at $0.2 in the last session, up 2.37% from day before closing price of $0.2. In other words, the price has increased by $2.37 from its previous closing price. On the day, 1.03 million shares were traded. PCSA stock price reached its highest trading level at $0.2049 during the session, while it also had its lowest trading level at $0.1961.
Ratios:
We take a closer look at PCSA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.45 and its Current Ratio is at 3.45. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on April 25, 2024, initiated with a Buy rating and assigned the stock a target price of $8.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 27 ’25 when Yorke Justin W bought 12,400 shares for $0.80 per share. The transaction valued at 9,889 led to the insider holds 12,400 shares of the business.
Ng George K bought 87,200 shares of PCSA for $69,542 on Jan 27 ’25. The Chief Executive Officer now owns 87,200 shares after completing the transaction at $0.80 per share. On Jan 27 ’25, another insider, Young David, who serves as the Pres. Research & Development of the company, bought 124,500 shares for $0.80 each. As a result, the insider paid 99,289 and bolstered with 205,405 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PCSA now has a Market Capitalization of 11325133 and an Enterprise Value of 3304806.
Stock Price History:
The Beta on a monthly basis for PCSA is 1.36, which has changed by -0.82941175 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, PCSA has reached a high of $1.50, while it has fallen to a 52-week low of $0.15. The 50-Day Moving Average of the stock is -2.90%, while the 200-Day Moving Average is calculated to be -47.89%.
Shares Statistics:
According to the various share statistics, PCSA traded on average about 5.03M shares per day over the past 3-months and 2984010 shares per day over the past 10 days. A total of 50.35M shares are outstanding, with a floating share count of 43.77M. Insiders hold about 13.07% of the company’s shares, while institutions hold 0.74% stake in the company. Shares short for PCSA as of 1757894400 were 909292 with a Short Ratio of 0.18, compared to 1755216000 on 1736240. Therefore, it implies a Short% of Shares Outstanding of 909292 and a Short% of Float of 1.6500000000000001.
Earnings Estimates
. The current rating of Processa Pharmaceuticals Inc (PCSA) is the result of assessments by 1.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.06 and low estimates of -$0.06.
Analysts are recommending an EPS of between -$0.43 and -$0.43 for the fiscal current year, implying an average EPS of -$0.43. EPS for the following year is -$0.15, with 1.0 analysts recommending between -$0.15 and -$0.15.
